Mikhaeel N George, Smith Daniel, Dunn Joel T, Phillips Michael, Møller Henrik, Fields Paul A, Wrench David, Barrington Sally F
Department of Clinical Oncology, Guy's and St Thomas' NHS Foundation Trust, Westminster Bridge Road, SE1 7EH, London, UK.
PET Imaging Centre at St Thomas' Hospital, Division of Imaging Sciences and Biomedical Engineering, King's College London, London, UK.
Eur J Nucl Med Mol Imaging. 2016 Jul;43(7):1209-19. doi: 10.1007/s00259-016-3315-7. Epub 2016 Feb 23.
The study objectives were to assess the prognostic value of quantitative PET and to test whether combining baseline metabolic tumour burden with early PET response could improve predictive power in DLBCL.
A total of 147 patients with DLBCL underwent FDG-PET/CT scans before and after two cycles of RCHOP. Quantitative parameters including metabolic tumour volume (MTV) and total lesion glycolysis (TLG) were measured, as well as the percentage change in these parameters. Cox regression analysis was used to test the relationship between progression-free survival (PFS) and the study variables. Receiver operator characteristics (ROC) analysis determined the optimal cut-off for quantitative variables, and Kaplan-Meier survival analysis was performed.
The median follow-up was 3.8 years. As MTV and TLG measures correlated strongly, only MTV measures were used for multivariate analysis (MVA). Baseline MTV (MTV-0) was the only statistically significant predictor of PFS on MVA. The optimal cut-off for MTV-0 was 396 cm(3). A model combing MTV-0 and Deauville score (DS) separated the population into three distinct prognostic groups: good (MTV-0 < 400; 5-year PFS > 90 %), intermediate (MTV-0 ≥ 400+ DS1-3; 5-year PFS 58.5 %) and poor (MTV-0 ≥ 400+ DS4-5; 5-year PFS 29.7 %)
MTV-0 is an important prognostic factor in DLBCL. Combining MTV-0 and early PET/CT response improves the predictive power of interim PET and defines a poor-prognosis group in whom most of the events occur.
本研究的目的是评估定量PET的预后价值,并测试将基线代谢肿瘤负荷与早期PET反应相结合是否能提高弥漫性大B细胞淋巴瘤(DLBCL)的预测能力。
共有147例DLBCL患者在接受两个周期的RCHOP治疗前后进行了FDG-PET/CT扫描。测量了包括代谢肿瘤体积(MTV)和总病变糖酵解(TLG)在内的定量参数,以及这些参数的变化百分比。采用Cox回归分析来测试无进展生存期(PFS)与研究变量之间的关系。通过受试者工作特征(ROC)分析确定定量变量的最佳临界值,并进行Kaplan-Meier生存分析。
中位随访时间为3.8年。由于MTV和TLG测量值相关性很强,因此在多变量分析(MVA)中仅使用MTV测量值。基线MTV(MTV-0)是MVA中PFS的唯一具有统计学意义的预测指标。MTV-0的最佳临界值为396 cm³。一个结合MTV-0和多维尔评分(DS)的模型将人群分为三个不同的预后组:良好(MTV-0<400;5年PFS>90%)、中等(MTV-0≥400+DS1-3;5年PFS 58.5%)和不良(MTV-0≥400+DS4-5;5年PFS 29.7%)。
MTV-0是DLBCL的一个重要预后因素。将MTV-0与早期PET/CT反应相结合可提高中期PET的预测能力,并确定一个大多数事件发生的预后不良组。